Drug Companies Failing To Provide Details on Clinical Trials, NEJM Editor Says
Main Category: Pharma Industry / Biotech IndustryArticle Date: 25 May 2005 - 11:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Jeffrey Drazen, editor in chief of the New England Journal of Medicine, said on Monday that three of the largest pharmaceutical companies... -- GlaxoSmithKline, Merck and Pfizer -- are "making a mockery" of efforts to offer more transparency in clinical trials by failing to provide accurate information about their studies, the AP/Hartford Courant reports. In September 2004, the members of the International Committee of Medical Journal Editors announced that they will cease publishing studies that are not registered in an NIH database -- ClinicalTrials.gov -- at the time of their launches. The Pharmaceutical Research and Manufacturers of America and three other major pharmaceutical associations earlier this year recommended to their members that they submit clinical trial information to the public registry beginning in July. Pharmaceutical companies are legally required to register trials for products treating serious or life-threatening diseases, but in recent months they have begun registering other types of studies on the site, as well as listing them on their own Web sites. Following a review of the information posted by 10 pharmaceutical companies on the registry, Drazen said that GSK, Merck and Pfizer are failing to provide useful data on clinical trials they register on the site. Drazen said the three companies provided inadequate information on the number of patients in trials and also failed to clearly outline primary and secondary goals of the trials. Drazen said the three companies are "giving nonsense details," adding, "They are written in a way that they are trying to hide what they are doing." Drazen said that a number of other companies have complied with the requirements -- including Eli Lilly and Abbott Laboratories, which are "90% in compliance" -- but that some companies recently have begun to follow the lead of GSK, Merck and Pfizer in their disclosures (Agovino, AP/Hartford Courant, 5/24).
"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/25092.php>
APA
http://www.medicalnewstoday.com/releases/25092.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



